Clinical Trial Search

Primary: 25% Reduction in Benzodiazepine Use — 14; 6 Participants

Primary: Participant Acceptability of the Interventions — 1; 0 Participants

Primary: Completion Rate — 26 percentage of successful completers

Primary: Mean Reduction Change in Benzodiazepine Use Per Day Based on Time Line Follow Back — 4.0; 2.3 milligrams/day

Primary: Drinking — 6; 8; 2 participants — p=<0.04

Primary: Participants With Withdrawal-Emergent Adverse Events — 9; 13 Participants

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg

Primary: Treatment Adherence — 15 Participants

Primary: Number of Subjects at Endpoint (Post Alprazolam Free Week 6 or Last Observation Carried Forward [LOCF] Post Alprazolam Free Week 1) Who Are Benzodiazepine Free — 20; 10…

Primary: Maximum 3-Day Moving Average (MA) of the Discontinuation Symptom Checklist-Modified Rickels Total Score — 13.23; 11.50 units on a scale — p=0.170

Primary: Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period — 11.22…

Primary: Epworth Sleepiness Scale (ESS) — 6.35; 2.65 units on a scale

Primary: Subjective Rating of Marijuana Craving on 1-7 Likert Scale — 1.64; 0.80 units on a scale

Primary: Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS) — 12.6; 1.3 units on a scale

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 — -966.00; -532.81 ng/ml — p=.029

Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 7.2; 6.4 percentage of UDS

Primary: Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire — 11; 11 units on a scale

Primary: Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again" — 0; 1.714; 2.143; 2.286 units on a scale

Primary: Visual Analog Scales of Similarity to Alcohol - Baseline — 0; 0; 0; 0 units on a scale

Primary: Number of Patients Requiring Continuous Lorazepam Infusion — 2; 16 participants

Primary: Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study — 14.00; 7.00; 10.00; 8.00 dollars

Primary: Mean Length of Hospital Stay — 44.91; 50.50 hours

Primary: Detoxification Phase: Changes in Percent of Illicit Opioid-positive Urine Samples Over Time — 35.0; 41.6 percentage of urine positive samples — p=0.77

Primary: Time to Cannabis Use Relapse — 1; 1 days

Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87

Primary: Maximum Tolerated Dose of Quetiapine — 197 milligrams

Primary: Peak SOWS Scores at Baseline and Over Time — 3.6; 5.2; 6.0; 4.7 score on a scale

Primary: Mean Percentage of Heavy Drinking Days — 39; 42; 28 percentage of heavy drinking days — p=0.018

Primary: Feasibility of Intervention — 67; 48 Percentage of participants

Primary: Change From Baseline in Drinking Quantity and Frequency Using Drinks Per Week at Week 12 — 42.07; 56.67; 41.20; 9.16 drinks/week